Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rubinstein

Showing results (541-550 of 558) with videos related to

Pageof 56
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial CancerAngela K Green, Qin Zhou, Alexia Iasonos, et al.
Msystems|June 1, 2021
Transcriptional Regulation of Plant Biomass Degradation and Carbohydrate Utilization Genes in the Extreme Thermophile <i>Caldicellulosiruptor bescii</i>Dmitry A Rodionov, Irina A Rodionova, Vladimir A Rodionov, et al.
Gynecologic Oncology|November 24, 2019
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancerMarina Stasenko, Irina Tunnage, Charles W Ashley, et al.
Blood Advances|February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in MyelomaWilliam A Wood, Shaji K Kumar, Emily Semmel, et al.
JAMA Oncology|June 17, 2021
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19Michael A Thompson, Jeffrey P Henderson, Pankil K Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial CancerMaria M Rubinstein, Jennifer Y Ge, Qin Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2022
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical ProfilesBeryl L Manning-Geist, Ying L Liu, Kelly A Devereaux, et al.
Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.
Nature Medicine|April 23, 2024
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analysesClaire F Friedman, Beryl L Manning-Geist, Qin Zhou, et al.
Scientific Reports|October 17, 2020
Seven decades of chemotherapy clinical trials: a pan-cancer social network analysisXuanyi Li, Elizabeth A Sigworth, Adrianne H Wu, et al.
Pageof 56

Showing results (541-550 of 558) with videos related to

Sort By:
Pageof 56
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2024
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial CancerAngela K Green, Qin Zhou, Alexia Iasonos, et al.
Msystems|June 1, 2021
Transcriptional Regulation of Plant Biomass Degradation and Carbohydrate Utilization Genes in the Extreme Thermophile <i>Caldicellulosiruptor bescii</i>Dmitry A Rodionov, Irina A Rodionova, Vladimir A Rodionov, et al.
Gynecologic Oncology|November 24, 2019
Clinical outcomes of patients with POLE mutated endometrioid endometrial cancerMarina Stasenko, Irina Tunnage, Charles W Ashley, et al.
Blood Advances|February 24, 2026
Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in MyelomaWilliam A Wood, Shaji K Kumar, Emily Semmel, et al.
JAMA Oncology|June 17, 2021
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19Michael A Thompson, Jeffrey P Henderson, Pankil K Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
A Phase II Trial of Olaparib Plus Pembrolizumab in Patients with Recurrent Copy-Number High/p53-Abnormal Endometrial CancerMaria M Rubinstein, Jennifer Y Ge, Qin Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2022
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical ProfilesBeryl L Manning-Geist, Ying L Liu, Kelly A Devereaux, et al.
Journal for Immunotherapy of Cancer|June 13, 2025
Phase II study of rucaparib and nivolumab in patients with leiomyosarcomaSujana Movva, Kenneth Seier, Martina Bradic, et al.
Nature Medicine|April 23, 2024
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analysesClaire F Friedman, Beryl L Manning-Geist, Qin Zhou, et al.
Scientific Reports|October 17, 2020
Seven decades of chemotherapy clinical trials: a pan-cancer social network analysisXuanyi Li, Elizabeth A Sigworth, Adrianne H Wu, et al.
Pageof 56